BEIJING, Sept. 30, 2016 /PRNewswire/ -- Sinovac Biotech
Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical
products in China, announced today
that it will hold its 2016 Annual Meeting of Shareholders on
Monday, November 7, 2016 at
9:00 a.m. Beijing Time. The meeting
will be held at No. 39 Shangdi Xi Road, Haidian District,
Beijing, PRC. All shareholders of
record as of September 23, 2016 will
be eligible to vote and are invited to attend.
The primary agenda of the meeting is to approve the re-election
of Weidong Yin, Yuk Lam Lo, Simon
Anderson, Kenneth Lee and
Meng Mei as the Company's directors
until the next annual meeting of shareholders and or until their
successors are duly elected; approve the audited consolidated
financial statements of the Company for the financial year ended
December 31, 2015 together with the
Report of Independent Registered Public Accounting Firm thereon and
the notes thereto; approve the appointment of Ernst &Young Hua
Ming LLP as the independent auditor of the Company for the fiscal
year ending December 31, 2016 and to
authorize the directors of the Company to fix such independent
auditor's remuneration.
Sinovac's 2015 annual report and proxy statements, including the
Notice of the 2016 Annual General Meeting, are available on the
Company's website: http://www.sinovac.com/?optionid=751
Shareholders of the Company may receive a hard copy of 20-F free
of charge upon request. Such request can be made by sending an
e-mail to ir@sinovac.com, along with complete contact details and a
mailing address.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacturing, and
commercialization of vaccines that protect against human infectious
diseases. Sinovac's product portfolio includes vaccines against
hepatitis A and B, seasonal influenza, H5N1 pandemic influenza
(avian flu), H1N1 influenza (swine flu), mumps and canine rabies.
In 2009, Sinovac was the first company worldwide to receive
approval for its H1N1 influenza vaccine, which it has supplied to
the Chinese Government's vaccination campaign and stockpiling
program. The Company is also the only supplier of the H5N1 pandemic
influenza vaccine to the government stockpiling program. Sinovac's
newly developed innovative vaccine against HFMD caused by EV71 is
ready for market launch. The Company is currently developing a
number of new products including a Sabin-strain inactivated polio
vaccine, pneumococcal polysaccharides vaccine, pneumococcal
conjugate vaccine and varicella vaccine. Sinovac primarily sells
its vaccines in China, while also
exploring growth opportunities in international markets. The
Company has exported select vaccines to Mexico, Mongolia, Nepal, Tajikistan, Bangladesh, Chile and the
Philippines, and was recently granted a license to
commercialize its influenza vaccine in Guatemala. For more information, please visit
the Company's website at www.sinovac.com.
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
levels of activity, performance or achievements to differ
materially from any future results, levels of activity, performance
or achievements expressed or implied by these forward looking
statements. Factors that might cause such a difference include our
inability to compete successfully in the competitive and rapidly
changing marketplace in which we operate, failure to retain key
employees, cancellation or delay of projects and adverse general
economic conditions in the United
States and internationally. These risks and other factors
include those listed under "Risk Factors" and elsewhere in our
Annual Report on Form 20-F as filed with the Securities and
Exchange Commission. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "expects," "intends," "plans," "anticipates," "believes,"
"estimates," "predicts," "potential," "continue," or the negative
of these terms or other comparable terminology. Although we believe
that the expectations reflected in the forward-looking statements
are reasonable, we cannot guarantee future results, levels of
activity, performance or achievements. The Company assumes no
obligation to update the forward-looking information contained in
this release.
Contact
Sinovac Biotech Ltd.
Helen Yang
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com
ICR Inc.
Bill Zima
U.S: 1-646-308-1707
Email: william.zima@icrinc.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sinovac-schedules-2016-annual-meeting-of-shareholders-300337138.html
SOURCE Sinovac Biotech Co., Ltd.